Home / Market News / $LMRI

$LMRI news and market catalysts

The 4 most recent market catalysts affecting $LMRI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

4 catalysts 1 high impact 2 bullish 0 bearish Healthcare Technology
Oct 5, 2026 Corporate Catalyst Neutral Impact 65
Truist Securities Initiates Coverage On Lumexa Imaging Hldgs with Buy Rating, Announces Price Target of $18
Truist Securities analyst Clarke Murphy has initiated coverage on Lumexa Imaging Hldgs (LMRI) with a 'Buy' rating and a price target of $18. This event is significant as new analys…
Sep 25, 2026 Corporate Catalyst Neutral Impact 65
Keybanc Initiates Coverage On Lumexa Imaging Hldgs with Overweight Rating, Announces Price Target of $18
Keybanc analyst Matthew Gillmor has initiated coverage on Lumexa Imaging Hldgs (LMRI) with an 'Overweight' rating and an $18 price target. This event is significant because new ana…
Aug 28, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Overweight on Lumexa Imaging Hldgs, Raises Price Target to $13
Barclays analyst Andrew Mok maintained an 'Overweight' rating on Lumexa Imaging Hldgs (LMRI) and raised the price target from $9 to $13. This action signals increased confidence fr…
Aug 12, 2026 Corporate Catalyst Bullish Impact 92
Lumexa Imaging Holdings Q2 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $264.200M Beat $263.113M Estimate
Lumexa Imaging Holdings (LMRI) announced its Q2 earnings, reporting adjusted EPS of $0.20, significantly surpassing the analyst consensus of $0.16. Sales also exceeded expectations…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.